• List all instances where a retest was conducted after obtaining an initial OOS or unexpected result, including final batch dispositions since January 1, 2015. Provide any associated investigations and CAPA for each instance.
• Revise and provide detailed OOS procedures to ensure that investigations into OOS results are conducted adequately.
• Provide a CAPA to improve overall quality oversight at your firm, including but not limited to improved procedures that ensure final quality unit approval of all investigations into deviations, atypical events, OOS results, and batch failures.
• Revise your stability protocol to include assay for active ingredient;
• Provide data to support that your stability test methods are stability indicating and can detect and quantify degradants; and
• Conduct analyses on retain samples representative of all your OTC drug products currently within expiry and distributed to the U.S. for which you do not have adequate supporting stability data.
• Timelines for process performance qualification for your OTC drug products, and a detailed process performance qualification protocol for each of your OTC drug products.
• A data-driven and scientifically sound process validation program that appropriately identifies sources of variability, and ensures oversight of intra-batch and inter-batch variation on an ongoing basis throughout the product lifecycle.
• A risk assessment for distributed OTC drug products produced by an unvalidated process. Your risk assessment should address products distributed to the U.S. and still within expiry.